Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

Long-term considerations: While short-term forecasting remains a priority, forecasters also keep an eye on medium and ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

Drilling down into the reasons behind that upward trend, all three purchaser groups reported increased consumer demand (83%) ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic ...

It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...